Seitz C, Schroeder S, Knopf P, Krahl A, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9:1683345 pubmed publisher

Lim S, Kim J, Jeon S, Shin M, Kwon J, Kim T, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496 pubmed publisher

Houtsma R, Hogeling S, Schuringa J. CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones. STAR Protoc. 2021;2:100864 pubmed publisher

Ho J, Wang L, Liu Y, Ba M, Yang J, Zhang X, et al. Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. Mol Ther Methods Clin Dev. 2021;21:237-246 pubmed publisher

Srivastava S, Furlan S, Jaeger Ruckstuhl C, Sarvothama M, Berger C, Smythe K, et al. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer Cell. 2021;39:193-208.e10 pubmed publisher

Wang S, Li M, Sun F, Chen C, Ye J, Li D, et al. Th17/Treg-cell balance in the peripheral blood of pregnant females with a history of recurrent spontaneous abortion receiving progesterone or cyclosporine A. Exp Ther Med. 2021;21:37 pubmed publisher

Barresi V, Napoli S, Spampinato G, Condorelli D, Signorelli S. Dectin-1 and TIM3 Expression in Deep Vein Thrombosis of Lower Limbs (DVTLL). J Clin Med. 2020;9: pubmed publisher

Ping Y, Li F, Nan S, Zhang D, Shi X, Shan J, et al. Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv. Front Cell Dev Biol. 2020;8:803 pubmed publisher

Bhattacharya P, Ellegård R, Khalid M, Svanberg C, Govender M, Keita A, et al. Complement opsonization of HIV affects primary infection of human colorectal mucosa and subsequent activation of T cells. elife. 2020;9: pubmed publisher

Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, et al. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer. 2019;19:895 pubmed publisher

Srivastava S, Salter A, Liggitt D, Yechan Gunja S, Sarvothama M, Cooper K, et al. Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell. 2019;35:489-503.e8 pubmed publisher

Yang H, Xie T, Li D, Du X, Wang T, Li C, et al. Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-κB/TNF-α pathway. Mol Metab. 2019;23:24-36 pubmed publisher

Finney O, Brakke H, Rawlings Rhea S, Hicks R, Doolittle D, López M, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129:2123-2132 pubmed publisher

de Boer B, Prick J, Pruis M, Keane P, Imperato M, Jaques J, et al. Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. Cancer Cell. 2018;34:674-689.e8 pubmed publisher

Gorris M, Halilovic A, Rabold K, van Duffelen A, Wickramasinghe I, Verweij D, et al. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. J Immunol. 2018;200:347-354 pubmed publisher

Ho T, LaMere M, Stevens B, Ashton J, Myers J, O Dwyer K, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016;128:1671-8 pubmed publisher

Fromentin R, Bakeman W, Lawani M, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016;12:e1005761 pubmed publisher

Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Mol Med. 2016;8:702-11 pubmed publisher

Poonia B, Pauza C. Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy. PLoS ONE. 2014;9:e88884 pubmed publisher

Fang L, Lowther D, Meizlish M, Anderson R, Bruce J, Devine L, et al. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol. 2013;15:1479-90 pubmed publisher

Wei F, Zhong S, Ma Z, Kong H, Medvec A, Ahmed R, et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci U S A. 2013;110:E2480-9 pubmed publisher

Zhang Y, Ma C, Wang J, Ji X, Wu X, Moorman J, et al. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol. 2012;91:189-96 pubmed publisher